Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02807844
Title Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

melanoma

endometrial carcinoma

pancreatic carcinoma

triple-receptor negative breast cancer

Therapies

MCS110 + Spartalizumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Dana Farber Cancer Center Boston Massachusetts 02215 United States Details
Washington University School of Medicine Saint Louis Missouri 63123 United States Details
The West Clinic Germantown Tennessee 38138 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Novartis Investigative Site Wilrijk 2610 Belgium Details
Novartis Investigative Site HUS FIN-00029 Finland Details
Novartis Investigative Site Saint Herblain cedex 44805 France Details
Novartis Investigative Site Frankfurt 60590 Germany Details
Novartis Investigative Site Ulm 89081 Germany Details
Novartis Investigative Site Hong Kong Hong Kong Details
Novartis Investigative Site Milano MI 20133 Italy Details
Novartis Investigative Site Milano MI 20141 Italy Details
Novartis Investigative Site Koto ku Tokyo 135 8550 Japan Details
Novartis Investigative Site Seoul 03080 Korea, Republic of Details
Novartis Investigative Site Seoul 05505 Korea, Republic of Details
Novartis Investigative Site Valencia Comunidad Valenciana 46010 Spain Details
Novartis Investigative Site Madrid 28009 Spain Details
Novartis Investigative Site Chur 7000 Switzerland Details
Novartis Investigative Site Geneve 14 CH 1211 Switzerland Details
Novartis Investigative Site Zuerich 8091 Switzerland Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field